FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway

[1]  Q. Jiang,et al.  Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  A. Warth,et al.  FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC , 2019, Cancers.

[3]  Weiqun Peng,et al.  miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer , 2018, Oncogene.

[4]  M. Xie,et al.  Long intergenic non-coding RNA 00324 promotes gastric cancer cell proliferation via binding with HuR and stabilizing FAM83B expression , 2018, Cell Death & Disease.

[5]  F. Pentimalli.  BCL2: a 30-year tale of life, death and much more to come , 2017, Cell Death and Differentiation.

[6]  W. Liu,et al.  High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation , 2017, Journal of Cancer.

[7]  A. Weaver,et al.  Quinacrine in endometrial cancer: Repurposing an old antimalarial drug. , 2017, Gynecologic oncology.

[8]  Hongwei Jin,et al.  Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding , 2017, Oncotarget.

[9]  Shinya Watanabe,et al.  FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma , 2015, International journal of oncology.

[10]  Rocky Cipriano,et al.  Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human Cancer , 2014, Molecular Cancer Research.

[11]  M. Jackson,et al.  FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies , 2013, Oncotarget.

[12]  Sarah A. Scott,et al.  FAM83B mediates EGFR- and RAS-driven oncogenic transformation. , 2012, The Journal of clinical investigation.

[13]  C. Niehrs,et al.  Mitotic and mitogenic Wnt signalling , 2012, The EMBO journal.

[14]  Konrad Basler,et al.  The many faces and functions of β‐catenin , 2012, The EMBO journal.

[15]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[16]  D. Oh,et al.  Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. , 2010, Cancer cell.

[17]  Maya Breitman,et al.  The armadillo repeat domain of the APC tumor suppressor protein interacts with Striatin family members. , 2008, Biochimica et biophysica acta.

[18]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[19]  K. Kinzler,et al.  The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. , 2000, Cancer research.

[20]  M. Klink,et al.  Adenosine analogues as opposite modulators of the cisplatin resistance of ovarian cancer cells. , 2019, Anti-cancer agents in medicinal chemistry.

[21]  Yoshinori Takahashi,et al.  Analysis of Protein-Protein Interaction by Co-IP in Human Cells. , 2018, Methods in molecular biology.

[22]  W. Weis,et al.  The β-catenin destruction complex. , 2013, Cold Spring Harbor perspectives in biology.

[23]  M. Leid,et al.  Detection of apoptosis by TUNEL assay. , 2012, Methods in molecular biology.

[24]  Celia Quevedo,et al.  Biochemical mechanisms of cisplatin cytotoxicity. , 2007, Anti-cancer agents in medicinal chemistry.

[25]  J. Lawry.  Detection of apoptosis by the TUNEL assay. , 2004, Methods in molecular medicine.